Skip to Content
  • Previous Rank
    276
  • Revenues ($M)
    $42,294.00
  • Revenue Percent Change
    5.4%
  • Profits ($M)
    $6,220.00
  • Profits Percent Change
    159.8%
  • Assets ($M)
    $82,637.00
  • Employees
    69,000

Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Kenneth C. Frazier
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, N.J.
Websitehttps://www.merck.com
Years on Global 500 List25
Employees69,000

Merck Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$42,294.005.4%
Profits ($M)$6,220.00159.8%
Assets ($M)$82,637.00-
Total Stockholder Equity ($M)$26,701.00-

Profit Ratios

Profit as % of Revenues14.7%
Profits as % of Assets7.5%
Profits as % of Stockholder Equity23.3%